Proteomics Technologies Market

Because a federal court struck down the Food and Drug Administration (FDA) rule that would have treated laboratory-developed tests (LDTs) as medical devices, US laboratories keep the right to validate mass-spectrometry protein panels in-house, and the proteomics technologies market inherits that freedom. The FDA published its implementation notice on 19 September 2025, deleting the 2024 wording after the 31 March 2025 vacatur and ending a phase-in that would have pushed in-house protein assays toward premarket review. Douglas Insights sizes the proteomics technologies market at USD 31.78 billion in 2025: 438,900 installed proteomics workflow systems multiplied by USD 72,400 of annual spend pulled through each one. By 2035 the total reaches USD 90.0 billion, a revenue CAGR of 10.97% built from 6.6% growth in installed systems and a 4.1% rise in spend per system. The study belongs to our life science instruments coverage and follows the published research methodology.

What does the proteomics technologies market include, from Orbitrap mass spectrometers to proximity extension assays?

Proteomics technologies are the instruments, reagents, software and services that identify and quantify proteins, and the market covers 438,900 installed workflow systems in 2025. Mass spectrometry, affinity proteomics, electrophoresis and western blotting, protein microarrays and chromatography all sit inside the boundary, alongside the outsourced runs and bioinformatics that turn spectra into protein tables.

A system, in our count, is any platform whose main output is protein identity or abundance: a liquid chromatography mass spectrometry (LC-MS) rig, a proximity extension assay (PEA) or aptamer readout, a gel imager, an array scanner or a protein sequencer. Clinical chemistry analysers and DNA sequencers that never run a protein assay fall outside. Buyers are pharmaceutical and biotechnology companies, academic and government institutes, clinical laboratories and contract research organisations.

The USD 72,400 average is not a sticker price. It is annual revenue per installed proteomics system: new instrument sales spread across the fleet, plus reagents, service contracts, software seats and outsourced runs. Consumables make up 63.4% of it.

Who wins proteomics platform contracts, from Thermo Fisher’s Olink to Bruker’s timsTOF?

Thermo Fisher Scientific leads proteomics technologies with a 16.4% share of 2025 value, about USD 5.21 billion, because it sells Orbitrap mass spectrometers, Olink affinity panels and the reagents feeding both. The top three suppliers hold 29.9% between them, so the field stays broad below the leader.

Thermo Fisher completed its purchase of Olink on 10 July 2024 for about USD 3.1 billion net of acquired cash, according to its tender offer filing, adding the Explore HT platform that the UK Biobank later chose for its 600,000-sample study. At the ASMS conference in June 2025 it added the Orbitrap Astral Zoom, which by the maker’s account scans 35% faster with 40% higher throughput. Danaher follows at 8.3%, USD 2.64 billion, through SCIEX ZenoTOF systems and Abcam antibodies. Merck KGaA takes 5.2% from MilliporeSigma antibodies, protein standards and sample-preparation kits.

Agilent Technologies holds 2.9%, USD 921.5 million, on columns, AssayMAP Bravo sample preparation and Q-TOF systems; Waters earns 2.2% from ACQUITY separations and Xevo detectors; Bio-Rad Laboratories takes 2.1% from western blotting chemistry and ChemiDoc imagers. Bruker earns an estimated 1.7%, USD 540.2 million, from timsTOF systems, about 17% of the USD 3.17 billion its scientific instruments segment reported for 2025, a year when its organic revenue fell 3.7%. Illumina joined the field on 30 January 2026, closing a USD 350 million cash purchase of SomaLogic with up to USD 75 million more in milestones and royalties.

All shares are Douglas Insights estimates: disclosed segment revenues multiplied by our proteomics attribution ratios, because no vendor reports proteomics revenue on its own line.

Which product line makes the money in proteomics: reagents, instruments, services or software?

Reagents and consumables earn 63.4% of proteomics technologies value in 2025, USD 20.1 billion. Every LC-MS run and affinity panel burns columns, enzymes, antibodies, labels and plates, while an instrument is bought roughly once a decade.

Reagents and consumables rise to USD 55.2 billion by 2035 at 10.61% a year, since panel plexity keeps climbing. Instruments hold USD 6.90 billion, a 21.7% share, and grow slowest at 9.18% because academic replacement cycles stretched in 2025. Proteomics services are the fastest line at 14.36% a year, from USD 3.27 billion to USD 12.5 billion, as drug developers outsource plasma studies too large for in-house cores. Software and bioinformatics take USD 1.46 billion, 4.6% of value, growing 13.71% as data-independent acquisition (DIA) files outgrow desktop tools.

Product-line values for 2035 sum to USD 89.6 billion, within 0.40% of the headline.

Proteomics value by technology

Mass spectrometry carries 41.8% of 2025 proteomics value, affinity proteomics 19.6%, electrophoresis and western blotting 14.9%, chromatography 13.2% and protein microarrays 5.7%. The remaining 4.8% covers single-molecule protein sequencing and label-free binding tools, profiled in the Surface Plasmon Resonance Market report.

How many proteins per plasma sample can an Orbitrap Astral or an Olink Explore HT panel read?

Up to 5,400 proteins per plasma sample is the depth the UK Biobank study buys from Olink Explore HT, and that figure now sets the commercial bar for proteomics technologies in population research.

The pilot read nearly 3,000 proteins from 54,000 participants; the new UK Biobank study is ten times larger. Mass spectrometry competes on a different axis: no fixed panel, so it finds modified and unexpected proteoforms that an antibody pair never targets. Douglas Insights estimates that a 2025 high-resolution proteomics instrument quantifies about 1.9 times as many proteins per plasma run as a 2020 model. Depth is now cheap. Interpretation is not.

Why are biobanks and drug hunters buying more protein measurements per plasma sample?

Installed proteomics systems grow 6.6% a year because four buyer groups add capacity at once: population biobanks add 2.3 points, biopharma discovery 1.9 points, clinical laboratories 1.2 points and Asia Pacific core facilities 1.2 points.

Biobanks contribute the largest 2.3 points. The UK Biobank Pharma Proteomics Project launched on 10 January 2025 with 14 biopharmaceutical funders, a first phase of 300,000 samples and a full scope of 600,000 samples, including 100,000 repeat draws taken up to 15 years apart; data releases begin in 2026 and the full set is due in 2027, per the UK Biobank announcement. Douglas Insights counts 3.24 billion protein measurements in that design alone, and every national biobank that copies it buys plates, sequencing readouts and analysis seats for proteomics technologies.

Biopharma adds 1.9 points. Target validation, biologics characterisation and post-translational modification (PTM) mapping each need protein-level evidence that RNA data cannot supply. Thermo Fisher paid about USD 3.1 billion for Olink, closing on 10 July 2024, according to its SEC filing, which shows how large a vendor rates pharma demand for high-plex panels. The Orbitrap Astral Zoom, launched in June 2025 with 50% expanded multiplexing, targets the same discovery queues. Douglas Insights reckons pharma and biotech buyers take 47% of 2025 proteomics spend, and their share of outsourced plasma studies rises fastest, which is why services outgrow instruments by more than 5 points a year.

Clinical laboratories add 1.2 points. After the 31 March 2025 court ruling and the Federal Register notice of 19 September 2025, US hospital and reference laboratories can keep running LC-MS protein assays under Clinical Laboratory Improvement Amendments (CLIA) certification without FDA premarket submissions. Douglas Insights expects clinical LC-MS proteomics systems to grow 9.8% a year to 2035, nearly half again faster than the overall installed base, with automation trends covered in the Clinical Lab Automation Market study.

Asia Pacific core facilities supply the last 1.2 points, matching the clinical contribution with 117,800 installed systems in 2025. Chinese, Indian, Japanese and Korean institutes are equipping national proteomics centres, and the region’s installed base grows about 9.9% a year in our model against 5.3% in North America. Together the four contributions sum to the 6.6% system leg. The 4.1% price leg sits on top: higher-plex panels, more outsourced runs and larger software seats raise spend per installed system each year.

What slows proteomics spending in academic mass-spectrometry cores?

Three restraints remove 1.7 points from the 6.6% proteomics system growth rate in the slower case, leaving 4.9% a year. Academic funding pressure takes 0.8 points, data-analysis bottlenecks 0.5 points and tariff and localisation friction 0.4 points.

Academic funding is the heaviest drag. Bruker’s full-year 2025 results showed revenue of USD 3.44 billion, up 2.1% as reported but down 3.7% organically, and its chief executive cited headwinds from academic funding, tariffs and currencies. University cores buy a large share of discovery mass spectrometers, so a frozen grant cycle delays instrument replacement by 1 to 2 years. Douglas Insights removes 0.8 points for it in the slower case.

Analysis is the second bottleneck, worth 0.5 points. A 600,000-sample, 5,400-protein dataset holds 3.24 billion values, and few laboratories employ enough proteomics bioinformaticians to quality-check it. Tariffs and localisation take the last 0.4 points: Chinese procurement increasingly favours domestic instruments, and imported proteomics systems carry higher landed costs in both directions.

Where do proteomics technologies grow fastest: North America, Europe or Asia Pacific?

North America leads proteomics technologies with USD 13.9 billion in 2025, 43.8% of value, because the largest drug-discovery budgets, the deepest network of academic cores and US laboratory-developed test freedom all sit there.

Asia Pacific is the fastest region at 13.47% a year, rising from USD 7.18 billion to USD 25.4 billion, as China, Japan, South Korea and India fund national proteomics centres and contract research organisations. By 2035 Asia Pacific holds 28.2% of value against Europe’s 23.8%. North America reaches USD 36.5 billion at 10.12% a year. Europe holds USD 8.55 billion in 2025 and grows 9.64%, the slowest, because In Vitro Diagnostic Regulation (IVDR) certification slows clinical kits and research budgets are flat. Latin America is worth USD 1.14 billion and grows 11.83%, led by Brazilian and Mexican pharma services. The Middle East and Africa is the wildcard: USD 984.9 million in 2025 growing 12.24%, where one Gulf population-health programme on the UK Biobank model would move the regional proteomics total by double digits.

How much does a laboratory pay per plasma proteome or LC-MS run?

Laboratories spend an average USD 72,400 a year per installed proteomics system in 2025, rising to USD 108,200 by 2035 on a 4.1% annual price leg driven by higher-plex consumables, outsourced runs and software seats.

Douglas Insights puts realised prices at about USD 0.9 million to USD 1.4 million for a high-resolution LC-MS proteomics system with its liquid chromatography front end, USD 0.3 million to USD 0.5 million for a triple-quadrupole clinical system, and USD 15,000 to USD 60,000 for a western blot imager. Outsourced high-plex affinity runs price at roughly USD 150 to USD 900 per plasma sample, and DIA mass-spectrometry services at USD 250 to USD 600 per sample. Wider instrument price trends are tracked in the Biotechnology Instruments Market report.

Unit costs fall while spend rises. Our index shows the cost of 1,000 protein measurements down 59% between 2020 and 2025, about 16.3% a year, yet proteomics budgets per system grow because each system now runs 1.64 times as many samples.

Which rules govern clinical proteomic assays now that the FDA laboratory-developed test rule is gone?

Three regimes govern clinical proteomics technologies in 2026: CLIA certification for US in-house tests, FDA device review for kits sold to other laboratories, and Regulation (EU) 2017/746 for in vitro diagnostics marketed in Europe.

The FDA rule of 6 May 2024, 89 FR 37286, would have phased device obligations onto laboratories that build their own tests. A Texas federal court vacated it on 31 March 2025 in American Clinical Laboratory Association v. FDA, and the September 2025 final rule restored the earlier wording of 21 CFR 809.3(a), estimating USD 1.42 billion in annualised net cost savings. The agency’s LDT page now reflects that position. Research-use-only proteomics instruments sit outside device law altogether, which is why most discovery spend never meets a regulator.

Europe moves the other way. The IVDR requires notified-body review for most protein biomarker kits, so vendors launch clinical proteomics assays in the United States first and in the EU 2 to 3 years later, by our estimate.

What if academic budgets or biobank programmes shift, and where do proteomics technologies land in 2035?

Proteomics technologies reach USD 90.0 billion in 2035 in the base case, on 6.6% system growth and a 4.1% price leg, with the installed base climbing to about 831,600 systems.

The slower case keeps academic grants flat through 2028 and delays second-wave biobanks, leaving the market at USD 71.6 billion, USD 18.4 billion below base. The faster case assumes the 31 March 2025 LDT vacatur holds and US clinical laboratories move protein panels into routine testing, while two more national biobanks match the UK design; value then reaches USD 111 billion. Sensitivity runs through the installed base: at 7.6% system growth instead of 6.6%, the 2035 value becomes USD 98.8 billion, USD 8.81 billion higher. Published forecasts span 11.1% to 14.6% a year, and our 10.97% sits below that floor because we book the 2025 academic contraction.

Douglas Exclusive: the Proteomics Throughput Index

The Proteomics Throughput Index is a Douglas Insights model built from 64 inputs: 26 platform specification sheets, 21 realised price observations and 17 laboratory workflow timings, with 2020 set to 100.

The index counts what a proteomics laboratory gets out of its fleet, not what it pays. Measurements per instrument hour more than tripled in five years, driven by faster scanning and multiplexed affinity readouts, while proteins per sample rose 87%. The composite, a geometric mean of the four components, reached 221 in 2025.

The finding: cheaper measurements create more work, not smaller bills. Measurements per dollar rose 2.44 times between 2020 and 2025, yet spend per installed proteomics system still grows 4.1% a year in our model, because laboratories answer each cost cut with larger cohorts and deeper panels. Vendors that sell per sample, not per instrument, capture that loop.

Which receipts and cross-checks stand behind the proteomics methodology?

438,900 systems × USD 72,400 = USD 31,776,360,000, written as USD 31.78 billion for 2025, and every regional and product-line table in this proteomics study reconciles to that figure.

Coverage spans 5 regions, 42 countries, 4 product lines, 5 technologies and 4 end-user groups. The model uses 312 data points: installed-base estimates by country, vendor segment disclosures, price observations, the 64 index inputs and 5 published growth rates. Regional system counts run from 6,100 in the Middle East and Africa to 179,300 in North America.

Three cross-checks follow. The lowest published 2024 proteomics estimate, grown one year at its own 13.0% rate, gives USD 31.2 billion, 1.9% below ours. The highest published 2025 figure is 31.1% above ours, a gap explained by its inclusion of routine clinical immunoassays. Product-line values for 2035 land within 0.40% of the headline, and 1.066 × 1.041 − 1 equals the 10.97% revenue growth rate.

Sources

1. Federal Register, FDA Laboratory Developed Tests; Implementation of Vacatur (final rule) (2025)
2. US Food and Drug Administration Laboratory Developed Tests (2025)
3. UK Biobank Launch of world's most significant protein study (2025)
4. SEC EDGAR Thermo Fisher completes acquisition of Olink (tender offer exhibit) (2024)
5. Illumina Illumina completes acquisition of SomaLogic (2026)
6. Bruker Investor Relations Bruker fourth quarter and full year 2025 results (2026)